Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ: SYRS) announced the grant of restricted stock unit (RSU) awards totaling 89,400 shares to three new employees as inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with one-quarter of the shares vesting on each anniversary of the grant date, contingent on continued service. This strategic move aims to attract talent as the company advances its clinical-stage pipeline targeting gene expression control in various cancers.
Syros Pharmaceuticals (SYRS) reported Q4 and full-year 2021 financial results, highlighting a net loss of $23.8 million for Q4 and $86.6 million for the year. Total revenues were $7.8 million in Q4 and $23.5 million for 2021, up from $5.7 million and $15.1 million respectively in 2020. Key upcoming milestones include reporting pharmacokinetic and safety data for SY-2101 and clinical activity from SY-5609 in pancreatic cancer in mid-2022. Syros maintains $143.4 million in cash, expected to cover operations into Q1 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) is set to host a live conference call and webcast on March 15, 2022, at 8:30 a.m. ET, to discuss its fourth quarter and full year 2021 financial results. The call can be accessed via phone at (866) 595-4538 for domestic calls and (636) 812-6496 internationally, using conference ID 9682507. Syros is advancing a clinical-stage pipeline with key products like tamibarotene and SY-2101 targeting myeloid malignancies and acute promyelocytic leukemia, respectively. A webcast will be available for 30 days post-event on Syros’ website.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the presentation of new preclinical data on its CDK12 inhibitor program at the AACR Annual Meeting 2022, scheduled from April 8-13 in New Orleans, Louisiana. The e-poster will reveal that the selective CDK12 inhibitor exhibits strong anti-tumor activity both in vitro and in vivo across various cancer models and shows improved effects when combined with DNA-damaging agents. Syros aims to nominate a development candidate from this program in the latter half of 2022.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in two virtual investor conferences in March. She will present at the Cowen 42nd Annual Healthcare Conference on March 7 at 12:50 p.m. ET and at the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET. Management will also hold one-on-one meetings. Archived recordings will be available on Syros' website.
Syros focuses on developing gene expression medicines with a diverse clinical pipeline, including treatments for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) has announced that the U.S. FDA granted orphan drug designation to tamibarotene for treating myelodysplastic syndrome (MDS). Tamibarotene, a selective retinoic acid receptor alpha agonist, is being evaluated in the SELECT-MDS-1 Phase 3 trial alongside azacitidine for RARA-positive HR-MDS patients. The drug's designation may offer benefits including market exclusivity and tax credits. Data from the trial is expected in late 2023 or early 2024, with potential new drug application filing anticipated in 2024.
Syros Pharmaceuticals (NASDAQ: SYRS) has announced significant advancements in its clinical programs. The company initiated an expansion cohort for SY-5609 combined with chemotherapy for pancreatic cancer patients, with results expected in late 2022. Additionally, a Phase 1 trial for SY-5609 in hematologic malignancies is set to begin in the second half of 2022, alongside the nomination of a new development candidate from the CDK12 program. Syros remains optimistic about three key clinical data readouts in 2022 and is in a strong financial position to support operations into 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in fireside chats at two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference will take place on November 23, 2021, with a pre-recorded chat available on-demand at 10:00 a.m. ET. The JMP Securities Hematology and Oncology Summit is scheduled for December 6, 2021, at 10:40 a.m. ET. Webcasts and archived recordings can be accessed on Syros' website. The company is focused on developing gene expression medicines and has a robust clinical pipeline.
Syros Pharmaceuticals (NASDAQ:SYRS) announced significant progress in its clinical trials, including the dosing of the first patient in the SELECT-AML-1 Phase 2 trial of tamibarotene and the dose confirmation study of SY-2101 in acute promyelocytic leukemia (APL). Financial results for Q3 2021 revealed revenues of $5.7 million, up from $3.8 million in Q3 2020, though the company reported a net loss of $26 million. Notably, SY-5609 showed clinical activity in difficult-to-treat tumors during a recent Phase 1 trial. The company expects existing funds to sustain operations into 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a conference call on November 5, 2021, at 8:30 a.m. ET, to discuss its third quarter 2021 financial results and corporate updates. Interested parties can join the call by dialing (866) 595-4538 domestically or (636) 812-6496 internationally, referencing conference ID 3287324. A webcast will be available on their website, with an archived replay accessible for 30 days.
Syros focuses on developing gene expression medicines and has a promising clinical pipeline, including treatments for various hematologic malignancies.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
